SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Acquisition

1 May 2015 07:00

RNS Number : 9497L
Oxford Instruments PLC
01 May 2015
 



 

Release date: 1 May 2015

 

Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).

 

Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").

 

The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.

 

MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:

 

· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.

 

Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.

 

In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).

 

 

 

Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:

 

Dial: +44 (0)20 3139 4830

PIN: 89662683#

 

 

 

- Ends -

 

Enquiries:

 

 

Oxford Instruments plc Tel: 01865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Tel: 020 3128 8100

Rachel Hirst / Jack Holden

 

Issued for and on behalf of Oxford Instruments plc

 

 

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

The first technology business to be spun out from Oxford University, Oxford Instruments objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect.

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAFLEDSDSEAF
Date   Source Headline
12th Jun 20269:25 amPRNTransaction in Own Shares
9th Jun 20267:00 amRNSPreliminary Results
1st Jun 20262:03 pmPRNTotal Voting Rights
1st Jun 20261:59 pmPRNIssue of Equity
27th May 20261:58 pmPRNHolding(s) in Company
22nd May 20268:30 amPRNTransaction in Own Shares
14th May 202610:15 amPRNIssue of Equity
8th May 20268:36 amPRNTransaction in Own Shares
1st May 20269:05 amPRNTotal Voting Rights
1st May 20269:00 amPRNTransaction in Own Shares
24th Apr 20268:32 amPRNTransaction in Own Shares
17th Apr 20268:48 amPRNTransaction in Own Shares
14th Apr 202611:07 amPRNHolding(s) in Company
14th Apr 20267:00 amRNSTrading Update
13th Apr 20262:10 pmPRNHolding(s) in Company
13th Apr 20269:15 amPRNHolding(s) in Company
10th Apr 20267:00 amPRNTransaction in Own Shares
7th Apr 202611:11 amPRNTransaction in Own Shares
1st Apr 20263:26 pmPRNHolding(s) in Company
1st Apr 20262:19 pmPRNTotal Voting Rights
30th Mar 20262:54 pmPRNHolding(s) in Company
27th Mar 20268:31 amPRNTransaction in Own Shares
25th Mar 20263:15 pmPRNHolding(s) in Company
20th Mar 20269:00 amPRNTransaction in Own Shares
20th Mar 20268:00 amPRNHolding(s) in Company
17th Mar 202610:00 amPRNHolding(s) in Company
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amPRNTransaction in Own Shares
5th Mar 20262:40 pmPRNHolding(s) in Company
5th Mar 20267:00 amPRNTransaction in Own Shares
4th Mar 20267:00 amPRNTransaction in Own Shares
3rd Mar 20267:00 amPRNTransaction in Own Shares
2nd Mar 202610:38 amPRNTotal Voting Rights
2nd Mar 20267:00 amPRNExtension of Share Buyback Programme
27th Feb 20267:00 amPRNTransaction in Own Shares
26th Feb 20267:00 amPRNTransaction in Own Shares
25th Feb 20267:00 amPRNTransaction in Own Shares
24th Feb 20267:00 amPRNTransaction in Own Shares
23rd Feb 20267:00 amPRNTransaction in Own Shares
20th Feb 20267:00 amPRNTransaction in Own Shares
19th Feb 20267:00 amPRNTransaction in Own Shares
18th Feb 20267:00 amPRNTransaction in Own Shares
17th Feb 20267:00 amPRNTransaction in Own Shares
16th Feb 20267:00 amPRNTransaction in Own Shares
13th Feb 20267:00 amPRNTransaction in Own Shares
12th Feb 20267:00 amPRNTransaction in Own Shares
10th Feb 20267:00 amPRNTransaction in Own Shares
9th Feb 20267:00 amPRNTransaction in Own Shares
6th Feb 20267:00 amPRNTransaction in Own Shares
5th Feb 20267:00 amPRNTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.